交易中 12-16 10:05:48 美东时间
-0.050
-0.20%
Tenable® (NASDAQ:TENB), the exposure management company, today announced a OneGov agreement with the U.S. General Services Administration (GSA) to deliver its FedRAMP-authorized Cloud Security solution to U.S.
12-11 22:14
Tenable Holdings, Inc., an exposure management company, announced that CFO Matt Brown and co-CEO Steve Vintz will present at the UBS Global Technology and AI Conference on December 2 in Scottsdale and the Barclays Annual Global Technology Conference on December 10 in San Francisco. More details, including webcasts, are available at investors.tenable.com. Tenable helps protect organizations from cybersecurity risks globally with its AI-powered pla...
11-18 14:00
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从46美元升至47美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从27美元升至31美元
10-31 10:25
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Tenable 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 第三季度营收达到2.524亿美元,同比增长11.2%,超出指导区间高端。营收增长主要由续约业务、Tenable One平台采用率提升和专业服务贡献推动。 **盈利能力:** 非GAAP营业利润率达到23.3%,较去年同期的19.8%显著提升。非GAAP营业收入为5,890万美元,同比增长约31%。非GAAP毛利率为81.6%,较去年同期的81.4%小幅上升。 **每股收益:** 非GAAP每股收益为0.42美元,同比增长31.3%(去
10-30 12:44
Tenable Holdings (NASDAQ:TENB) raises FY2025 GAAP EPS guidance from $(0.46)-$(0.38) to $(0.34)-$(0.31) vs $(0.36) analyst estimate..
10-30 04:19
Tenable Holdings (NASDAQ:TENB) is looking for Q4 GAAP EPS of $(0.05)-$(0.02) vs $(0.01) analyst estimate..
10-30 04:19
Tenable Holdings (NASDAQ:TENB) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.37 by 13.82 percent. This is a 31.25 percent increase over earnings of $0.32 per share from
10-30 04:08
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
Tenable Holdings (NASDAQ:TENB) is set to give its latest quarterly earnings rep...
10-29 03:04
今日重点评级关注:Guggenheim:上调Neumora Therapeutics评级至"买入",目标价14美元;韦德布什:上调Fate Therapeutics评级至"跑赢大市",目标价从5美元升至7美元
10-28 10:08